title: Detecting and controlling diabetic nephropathy: what do we know?
abstract: Diabetic nephropathy is becoming increasingly common with the aging of our population and the obesity epidemic. The major ways to prevent or slow its progression are by reducing blood pressure, controlling blood sugar, and inhibiting the renin-angiotensin-aldosterone axis. New therapeutic agents are also being tried.
authors.affiliation: Clinical Nephrology, Columbia University, New York, NY 10032, USA. gba2@columbia.edu
authors.forename: Gerald
authors.initials: G
authors.lastname: Appel
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D009828:Oleanolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D012084:Renin-Angiotensin System
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007004:Hypoglycemic Agents; D009828:Oleanolic Acid; C445068:bardoxolone methyl